Key Points {#FPar1}
==========

WS 1442 has been shown to be effective in reducing symptoms, increasing the functional capacity, and improving the quality of life of patients with New York Heart Association class II or III heart failure.Several clinical trials have demonstrated the safety of WS 1442 in patients suffering from heart failure, including those with concomitant use of other co-medications like β-blockers, angiotensin-converting enzyme inhibitors, diuretics, and cardiac glycosides (digoxin and digitoxin).Further clinical trials have demonstrated that WS 1442 has a positive benefit-risk assessment for the treatment of heart failure with preserved and reduced ejection fraction.

Introduction {#Sec1}
============

The phrase "first do no harm" has been ascribed to Hippocrates (about 460--370 B.C.), but was actually coined by the British physician Thomas Inman as recently as 1860 \[[@CR1], [@CR2]\]. The intention behind the dictum is to remind physicians that they ought to always act in the best interest of their patients. Most medical treatments are inevitably associated with certain risks to the patient; these consequences may be more or less serious and more or less likely to occur depending on the patient and his/her circumstances. Physicians and patients may nevertheless be inclined to accept certain treatment emergent risks if they are outweighed by the expected therapeutic benefit. It is therefore important to assess the over-all risk-benefit ratio of any medical treatment.

Preparations from leaves and flowers of certain species of *Crataegus* (hawthorn) have been mentioned as remedies in the medical literature since the 1st century A.D. \[[@CR3]\], mainly for treating cardiac diseases and for strengthening the aging heart. In 1896, 43 cases of patients suffering from various forms of heart disease and treated with *Crataegus oxyacantha* were reported, with promising results \[[@CR4]\]. But it was not until the 1930s that systematic scientific research into the clinical effects of *Crataegus* preparations started, and extracts from *Crataegus* were introduced into the German pharmacopoeia in 1941. In 1984 and 1994, the German Commission E issued positive monographs for *Crataegus* leaves with flowers \[[@CR5]\] for the treatment of decreasing functional capacity of the heart corresponding to class II of the New York Heart Association (NYHA) Functional Classification, which is characterized by mild cardiac symptoms such as fatigue, palpitation, dyspnea, or anginal pain during ordinary activity \[[@CR6]\]. As medicinal products containing *Crataegus* leaves and flowers have been in use for at least 30 years (15 years within the EU), in 2016, the European Medical Association (EMA), through the Committee on Herbal Medicinal Products (HMPC), recognized the traditional use of *Crataegus* for the relief of symptoms of temporary nervous cardiac complaints (after serious medical conditions have been excluded) \[[@CR7]\]. Regarding the safety profile of this product, the EMA concluded that the use of *Crataegus* leaves and flowers can be regarded as safe when used under the approved indications \[[@CR8]\].

WS 1442[1](#Fn1){ref-type="fn"} is a dry extract from hawthorn leaves with flowers (4--6.6:1), extraction solvent of ethanol 45% (w/w). The extract is adjusted to 17.3--20.1% oligomeric procyanidins (OPCs). In addition to OPCs, the extract contains several flavonoids, including hyperoside, vitexin-rhamnoside, rutin, and vitexin as well as triterpenoids and phenol carboxylic acids. WS 1442 complies with the requirements of the European pharmacopoeia.

The safety and efficacy of *Crataegus* containing products have been studied and reviewed extensively \[[@CR9], [@CR10]\], and WS 1442 is probably the most rigorously studied extract on the market. This work provides a comprehensive overview of the safety and efficacy of WS 1442 in NYHA class II and III heart failure and assesses the risk-benefit ratio of the product, also considering different types of heart failure, i.e., systolic heart failure \[heart failure with reduced ejection fraction (HFrEF)\] and diastolic heart failure \[heart failure with preserved ejection fraction (HFpEF)\].

Pharmacology and Nonclinical Data, Mode of Action {#Sec2}
=================================================

In vitro experiments with human myocardial tissue demonstrated a positive inotropic effect of WS 1442 and a concentration-dependent increase of myocardial contractility accompanied by a transient rise in intracellular calcium \[[@CR11], [@CR12]\]. The effect is likely mediated by cyclic adenosine monophosphate (cAMP)-independent inhibition of sodium-potassium-ATPase, and is accompanied by an improved energy turnover of myocytes \[[@CR12]--[@CR14]\]. In contrast to cardiac glycosides, WS 1442 prolongs the action potential and the refractory period, and possesses pronounced anti-arrhythmic properties \[[@CR15]\]. WS 1442 enhances the relaxant effect of the nitric oxide (NO) donor nitroprusside and increases the release of NO from the endothelium while possibly inhibiting the NO degradation due to the antioxidative properties of WS 1442 \[[@CR16]\]. The extract causes endothelium-dependent vasorelaxation by an NO-mediated mechanism via endothelial NO synthase (eNOS)-phosphorylation at serine 1177 \[[@CR17], [@CR18]\]. Increased endothelial NO availability delays activation of the local angiotensin system and endothelial senescence \[[@CR19]\]. Endothelium-derived hyperpolarizing factor contributes to the vasorelaxing activity of WS 1442, most likely due to reduced vascular oxidative stress \[[@CR20]\]. Moreover the compound enhances microcirculation by reducing endothelial surface layer height and stiffness \[[@CR21]\] as well as by increasing red blood cell (RBC) NO formation \[[@CR22]\] and RBC surface negativity \[[@CR23]\]. Chronic administration of WS 1442 leads to a dose-dependent increase in myocardial basal vessel blood flow \[[@CR24]\] and prevents deoxycorticosterone acetate (DOCA) salt-induced hypertension and alterations of cardiac, vascular, and renal structure and function \[[@CR25]\].

In animal models of short-term ischemia and reperfusion, WS 1442 caused a significant reduction of ventricular fibrillation, tachycardia, and hypotensive crisis \[[@CR15], [@CR26]\]. Protection against reperfusion injury as well as reduction of ST segment elevation after reperfusion and ventricular fibrillation, infarct size, and mortality were also observed in rats \[[@CR27]\]. An increased coronary blood flow as well as reduced endothelial dysfunction, inhibition of lipid oxidation and anti-inflammatory properties may contribute to the cardioprotective effects of WS 1442 \[[@CR28]\]. Sustained, maladaptive cardiac hypertrophy related to physiological stimuli, such as hypertension, valvular disease, or myocardial infarction, has been recognized as a leading cause of cardiac insufficiency \[[@CR20]\]. WS 1442 lowered the hypertensive blood pressure and inhibited the development of cardiac hypertrophy in rats, while it had no effect in normotensive control animals \[[@CR25], [@CR29]\]. In pressure overload-related cardiac hypertrophy, a reduction of enlarged left ventricular chamber volume and augmented wall thickness was observed \[[@CR30], [@CR31]\].

In a rat model of endotoxin shock, WS 1442 significantly reduced the deterioration of cardiac output and prevented an increase in peripheral resistance. Since the extract did not affect peripheral blood pressure or heart rate, the increased cardiac output is presumably related to improved ventricular diastolic filling and enhanced myocardial contractility \[[@CR32]\]. There is pre-clinical evidence that WS 1442 may have a beneficial effect on human lipid metabolism \[[@CR9]\]. For example, an in vitro experiment using human Hep-G2 cells showed that WS 1442 causes a dose-dependent inhibition of apolipoprotein-B secretion and thereby decreases the formation of oxygenated low-density lipoprotein (LDL), from which a prophylactic effect against atherosclerosis may be expected \[[@CR33], [@CR34]\].

Most of the beneficial effects of WS 1442 on the myocardium, notably its cardioprotective properties, are closely related to the OPC to which the extract is adjusted \[[@CR16], [@CR27], [@CR28]\].

Hecker-Niediek \[[@CR35]\] determined the absorption and distribution of the radioactivity of ^14^C-labeled catechins, a trimeric procyanide, an OPC total fraction and higher OPCs after intravenous and oral administration in mice. Total radioactivity was measured in blood and different organs without determination of individual metabolites. One hour after oral administration, absorption of radioactivity could already be detected for all labeled substances. The absorption rate for the OPC total fraction was about 31%, and the rates for individual substances ranged from 16 to 40%. After repeated oral administration, the accumulation of radioactivity was higher than after a single dose.

In studies conducted with rats, WS 1442 doses of up to 3000 mg/kg body weight did not cause any chemical, hematological, morphological, or histological abnormalities or genotoxicity and had no influence on peri- or post-natal development \[[@CR9]\].

Clinical Safety and Tolerability {#Sec3}
================================

A comprehensive systematic review of the safety profile of *Crataegus* species, covering all clinical studies and post-marketing surveillance projects with hawthorn monopreparations published in or before January 2005, was presented by Daniele et al. \[[@CR36]\]. The authors identified 14 studies with WS 1442, of which ten were randomized, controlled trials, two were uncontrolled trials, one was an observational study, and one was a cohort study. In these projects, a total of 1563 subjects (controlled clinical trials: 395; uncontrolled studies: 1168) were exposed to the herbal medicinal product and received daily doses of up to 1800 mg for treatment periods of up to 16 weeks in clinical trials and 2 years in post-marketing surveillance projects. One trial was performed in healthy volunteers, while the participants of all other studies suffered from heart failure corresponding to NYHA classes I--II or II--III.

In the randomized trials included in the review and presenting data on adverse events (AEs), 30 of 356 patients treated with WS 1442 and 34 of 299 receiving placebo or a reference drug reported AEs with any causal relationship. In the trials reviewed, AE incidence in patients treated with WS 1442 was generally on a placebo level. There was no apparent relationship between WS 1442 dose and AE manifestation. In one double-blind study investigating daily doses of 1800 and 900 mg/day WS 1442 compared to placebo during 16 weeks of treatment, the proportions of patients with any AEs were 26.1, 28.6, and 51.4%, respectively, and therefore lower in patients treated with WS 1442 than in placebo-treated patients \[[@CR37]\]. The authors of the review interpreted this result to be an indicator of treatment efficacy rather than of safety, since WS 1442 appears to prevent, rather than elicit, symptoms like dizziness that are frequently reported as AEs \[[@CR36]\]. In an observational study included in the review, which monitored 1011 patients with heart insufficiency stage NYHA II treated with WS 1442 over a period of 24 weeks, 98.7% of physicians noted a "good" or "very good" tolerance to the treatment, with only 14 AEs \[[@CR38]\]. Moreover, in any of the studies reviewed, none of the AEs potentially related to WS 1442 were serious.

One of the merits of the review of Daniele et al. \[[@CR36]\] is that their search strategy assured a comprehensive overview of the literature available at the time of its publication regarding potential risks associated with *Crataegus* extract. Limitations include the lack of a comprehensive overview of the study selection criteria and of an assessment of the methodological quality and validity of the trials (the authors appear to have accepted all identified studies conducted with *Crataegus* monopreparations irrespective of their methodological quality, unless they were duplicate publications of other work). Since the publication of the review, additional clinical trials involving WS 1442 have been published:

The SPICE (Survival and Prognosis: Investigation of *Crataegus* Extract WS 1442 in congestive heart failure) trial reported by Holubarsch et al. \[[@CR39], [@CR40]\] was a placebo-controlled, double-blind, multicenter trial in which 2681 adults with NYHA class II or III congestive heart failure and reduced left ventricular ejection fraction (LVEF ≤ 35%) were randomized to receive 900 mg/day WS 1442 (*n* = 1338) or placebo (*n* = 1343) for a total duration of 24 months. At baseline, the average LVEF was 24%, and thus a substantial percentage of the study participants were at a high risk of cardiac mortality. WS 1442 was administered as an add-on treatment to guideline cardiac medication, and thus digoxin or digitoxin, diuretics, β-blockers, and angiotensin-converting enzyme (ACE) inhibitors were permitted as concomitant medication in any clinically appropriate combination or dose. In fact, about 90% of the study participants took at least three concomitant cardioactive drugs: about 85% of the patients in each group were administered diuretics, 83% received ACE inhibitors, 64% were treated with β-blockers, and 56% were administered digitalis or nitrates; concomitant antiarrhythmics were used by about 22% of the study participants, implicating possible proarrhythmic effects \[[@CR41], [@CR42]\].

With a sample size of about 1340 patients in each group, the SPICE study had a 95% chance of observing at least one AE whose true incidence in the population is at least 2.2‰ and was thus suited for observing even less frequent complications or drug--drug interactions. During the 2-year follow-up, 67.0% of the patients randomized to WS 1442 and 68.3% of those in the placebo group reported AEs, corresponding to one event in 388 and 370 days of exposure, respectively. Serious AE rates were 39.2 and 41.1%, respectively. The types of AEs were very similar in both treatment groups, and no specific AEs related to WS 1442 were observed \[[@CR40]\].

The Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial published by Zick et al. \[[@CR43], [@CR44]\] investigated the effect of 6 months' randomized, double-blind, add-on therapy with WS 1442 or placebo on submaximal exercise capacity in patients with NYHA class II--III chronic heart failure. A total of 120 patients participated, 60 of whom received WS 1442. Any AEs were experienced by 36 patients in the WS 1442 group (60.0%) and by 23 patients (38.3%) in the placebo group. However, 12 patients in each group (20.0%) reported cardiac-related AEs, and their incidences as well as those of common AEs like infections, rash, gastrointestinal complaints, and headache were also comparable. The authors concluded that the difference in the over-all AE rate was unlikely explainable by a pharmacological effect of WS 1442 and may have been attributable to chance. Zick et al. \[[@CR44]\] also observed a higher rate of heart failure progression (composite secondary endpoint of death, hospitalization, and increased diuretic use) in the early phase of the trial under WS 1442 as compared to placebo, although the difference disappeared in the course of the 6-month follow-up. The authors interpret this as an indicator that WS 1442 could increase the early risk of heart failure, but also warn that these findings could be due to chance and must be interpreted with caution, since they come from a post hoc analysis of an outcome measure not pre-specified before unblinding, which was performed in a relatively small study (120 patients) with a limited absolute number of heart failure events (28/60 and 26/60 patients for WS 1442 and placebo, respectively). The results of Zick et al. \[[@CR44]\] are also not supported by the SPICE trial \[[@CR40]\], in which 2681 patients were observed for up to 2 years. In contrast to Zick et al. \[[@CR44]\], the heart failure hazards in the SPICE trial were proportional over time, and no signals for an increased risk of heart failure under treatment with WS 1442 were observed, neither during the initial months of treatment, nor at any other time during follow-up.

Another randomized, controlled, exploratory trial was performed by Härtel et al. to investigate the effect of endurance exercise training and add-on medication with WS 1442 in patients with HFpEF meeting NYHA class II criteria \[[@CR45]\]. A total of 140 patients on guideline cardiac medication received 8 weeks of aerobic endurance training, and 70 of them were randomized to additional, open-label administration of 900 mg/day WS 1442. AEs with any causal relationship were observed in nine patients in the WS 1442 group (12.9%) and in 12 patients in the control group (17.1%). Most events were musculoskeletal complaints and injuries (possibly related to exercise training) and infections. None of the events reported in the WS 1442 group were assessed to be related to the herbal medicinal product.

Signals for possible drug interactions with WS 1442 were not observed in any of the studies reviewed by Daniele et al. \[[@CR36]\], nor in those published after completion of their review \[[@CR40], [@CR43], [@CR45]\], nor in literature searches that also included spontaneous reports to health authorities about suspected adverse reactions to hawthorn containing products \[[@CR9], [@CR46]\]. In a randomized, crossover, interaction study in healthy volunteers, concurrent administration of WS 1442 had no effect on the pharmacokinetic properties of digoxin \[[@CR47]\].

Clinical Efficacy {#Sec4}
=================

Treatment of heart failure is aimed at reducing morbidity and hospitalization as well as at improving heart failure emergent symptoms and health related quality of life (QoL). While trials investigating the efficacy of treatment in heart failure have previously focused mainly on mortality, current heart failure disease management guidelines increasingly recognize the importance of improving symptoms and QoL as patient-relevant outcomes. An example of this shift is a change in the description of the objectives of heart failure treatment between the European Society of Cardiology "Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure" of 2008 and 2012: whereas in the 2008 document it is stated that "The purpose of diagnosing and treating heart failure is no different from any other medical condition, namely to bring about a reduction of mortality and morbidity" \[[@CR48]\] (p. 2404), the authors of the 2012 revision recognize that "The goals of treatment in patients with established heart failure are to relieve symptoms and signs ..., prevent hospital admission, and improve survival" \[[@CR49]\] (p. 1804). In addition to improving survival and reducing hospitalization, the relief of symptoms such as dyspnea, fatigue, tiredness, or edema, as well as improvement in QoL and an increase in functional capacity, are thus also of the utmost importance to patients \[[@CR50]\]. Moreover, a lack of improvement in health-related QoL after hospital discharge has been identified as a powerful predictor of re-hospitalization and mortality \[[@CR51]\].

Survival {#Sec5}
--------

The effect of WS 1442 on mortality and hospitalization in NYHA class II--III HFrEF was investigated in the SPICE study, a 24-month, randomized, placebo-controlled trial \[[@CR39], [@CR40]\]. The primary endpoint was the time until the first cardiac event, defined as a composite endpoint of death of cardiac cause, non-fatal myocardial infarction, or hospitalization due to progressive heart failure. During 2 years of treatment, cumulative first cardiac event rates were lower with WS 1442 compared to placebo, albeit without reaching statistical significance (Fig. [1](#Fig1){ref-type="fig"}). Moreover, participants treated with WS 1442 were at a lower cumulative risk of cardiac mortality and sudden cardiac death (Fig. [2](#Fig2){ref-type="fig"}), notably in patients with baseline LVEF between 25 and 35% (upper limit for inclusion). In this subset, the difference with respect to placebo was descriptively significant at months 12, 18, and 24 in favor of WS 1442 for sudden cardiac death (Fig. [3](#Fig3){ref-type="fig"}). The results point to a potential antiarrhythmic and/or anti-ischemic effect already observed in animal models, where WS 1442 prevented reperfusion arrhythmias effectively. This is particularly important considering adverse reactions to chemical antiarrhythmics including amiodarone, since the reduction of the risk of sudden cardiac death was accomplished by WS 1442 without observing adverse reactions.Fig. 1Cumulative hazard for time to first cardiac event (from \[[@CR40]\]) Fig. 2Cumulative hazard for cardiac mortality (**a**, **c**) and sudden cardiac death (**b**, **d**): all patients (**a**, **b**) or patients with LVEF ≥ 25% (**c**, **d**) (from \[[@CR40]\]). *LVEF* left ventricular ejection fraction Fig. 3Cardiac mortality and sudden cardiac death in total population and subgroup LVEF ≥ 25% (hazard ratios, 95% confidence intervals and two-sided log-rank test *p* values) (from \[[@CR40]\]). *LVEF* left ventricular ejection fraction

Quality of Life and Exercise Tolerance {#Sec6}
--------------------------------------

The effect of WS 1442 on symptoms of heart failure and QoL-related outcomes was investigated in several smaller trials, most of which were included in a Cochrane review of hawthorn extracts for treating chronic heart failure \[[@CR52]\]. The authors identified 28 and included 14 trials which were performed in patients using a hawthorn monopreparation and which were randomized and placebo controlled. Of the 14 eligible trials, 11 used WS 1442, while three used LI 132, a methanolic extract standardized to a content of 2.2% flavonoids. For WS 1442, the effect on symptoms and/or health-related QoL was also investigated in controlled studies completed only after finalization of the Cochrane review \[[@CR40], [@CR43], [@CR45]\].

Exercise tolerance tests were performed in four trials included in the Cochrane review \[[@CR37], [@CR53]--[@CR55]\]. A meta-analysis of maximum workload (Fig. [4](#Fig4){ref-type="fig"}), in which the WS 1442 900 and 1800 mg/day groups investigated by Tauchert \[[@CR37]\] were analyzed separately, showed a statistically significant increase over placebo by a weighted mean difference of 5.4 W \[95% confidence interval (CI) 0.7--10.0, *p* = 0.024\]. Moreover, based on a meta-analysis of two trials \[[@CR54], [@CR55]\], the exercise tolerance was increased significantly by a weighted mean difference of 122.8 W min (95% CI 32.7--212.8, *p* \< 0.01).Fig. 4Maximum workload (W): meta-analysis of difference between *Crataegus* and placebo for change from baseline (means and 95% confidence intervals, random effects model)Data from \[[@CR52]\], Fig. 1.1, based on studies reported by Bödigheimer and Chase \[[@CR53]\] (LI 132), Hanak and Brückel \[[@CR54]\], Tauchert \[[@CR37]\] and Zapfe \[[@CR55]\] (all WS 1442)

The pressure-heart rate product, an index of cardiac oxygen consumption, was assessed in five trials included in the Cochrane review \[[@CR55]--[@CR59]\] and performed with WS 1442. Compared to placebo, meta-analysis showed a significant reduction of the pressure-heart rate product in WS 1442-treated patients by a weighted mean difference of 19.2 mmHg/min (95% CI 8.0--30.5, *p* \< 0.01) as well as significant reductions in four of the five primary trials \[[@CR52]\]. The results indicate a significant increase in cardiac performance in patients treated with WS 1442.

In patients with HFrEF, Eichstädt et al. \[[@CR60]\] as well as Zick et al. \[[@CR43]\] observed improvements of reduced LVEF, with moderate but statistically significant advantages for WS 1442 over placebo (*p* \< 0.01 and *p* = 0.04, respectively).

In the trial performed by Härtel et al. \[[@CR45]\] in 140 patients with HFpEF, in which 8 weeks of exercise training (bi-weekly, 90-min, supervised training sessions and aerobic walking) alone (70 patients) was compared to exercise training plus 900 mg WS 1442 per day, physical exercise capacity was analyzed by a 2-km walking test performed at baseline and treatment end (70 patients). Whereas patients randomized to WS 1442 showed a reduction of the time needed to accomplish the 2-km distance from an average of 23.0 to 20.1 min (reduction of 12.7% of the baseline value), the patients in the control group showed a reduction from 21.4 to 19.6 min (−8.4%). The difference was statistically significant (*p* = 0.02; Fig. [5](#Fig5){ref-type="fig"}). In patients with HFrEF, Zick et al. \[[@CR43]\] found an increase in 6-min walking distance from an average of 358 to 371 m for WS 1442 and from 374 to 379 m for placebo, but the difference was not significant at the 5% level.Fig. 5Time for 2-km walking test (means and standard deviations; data from \[[@CR45]\])

Changes in heart failure-associated symptoms and health-related QoL during treatment with WS 1442 were assessed in several trials \[[@CR37], [@CR43], [@CR45], [@CR56], [@CR57]\]. In two trials, the von Zerssen Complaints List \[[@CR61]\], a validated self-rating questionnaire assessing 24 general symptoms, some of which (e.g., shortness of breath, fatigue) are particularly important in heart failure, was used. In the study reported by Leuchtgens \[[@CR56]\], which included 30 patients (15 per group), those treated with WS 1442 for 8 weeks showed a significantly more pronounced decrease of the total score of the scale than those in the placebo group (mean value difference 7.3 points, 95% CI 0.9--13.7, according to \[[@CR52]\]). In the study of Tauchert \[[@CR37]\] in which 209 patients received 1800 or 900 mg/day WS 1442 or placebo for 16 weeks, both WS 1442 dosages showed a significantly more pronounced total score decrease compared to placebo (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Reduction in the total score of von Zerssen Complaints (means, standard deviations, and two-sided *p* values; from \[[@CR37]\], Fig. [4](#Fig4){ref-type="fig"}, and \[[@CR81]\])

Tauchert \[[@CR37]\] also used an ad hoc score assessing the four "typical" heart failure symptoms, i.e., general capability, lassitude, early fatigability, and effort dyspnea. At the end of the 16-week treatment phase, the treatment group differences to placebo for score change versus baseline were significant for WS 1442 900 mg/day (*p* = 0.04) and 1800 mg/day (*p* = 0.004).

Weikl et al. \[[@CR57]\] used a health-related QoL inventory developed by Siegrist and Junge \[[@CR62]\] for chronically ill patients and including items focusing on functional capacity (symptom burden, ability to enjoy and relax, positive and negative mood, sociableness, and allegiance). The authors report on a trend towards more pronounced improvement of all symptoms assessed in patients treated with WS 1442 as compared to placebo. During the baseline examination, the 136 patients included in the trial were also asked to identify and rate their main symptoms and complaints associated with heart failure. After 8 weeks of treatment, improvement of these symptoms was observed in 59% of 63 patients exposed to WS 1442 and in 44% of 68 patients treated with placebo.

The EuroQol-5D questionnaire \[[@CR63]\] was used in the study of Zick et al. \[[@CR43]\] for assessing health-related QoL after 6 months' treatment with WS 1442 or placebo in 120 patients. No significant differences were found.

In an open-label, exploratory study, Härtel et al. \[[@CR45]\] used the Kansas City Cardiomyopathy Questionnaire (KCCQ) \[[@CR64]\], specifically developed for assessing QoL in patients with chronic heart failure, to investigate 140 patients with HFpEF undergoing 8 weeks' endurance exercise training with or without co-administration of WS 1442. The study was neither intended nor powered for demonstrating superiority of WS 1442 co-administration, and, moreover, the authors observed a ceiling effect in some of the KCCQ subscales already in patients undergoing exercise training alone so that further improvement in WS 1442-treated patients could hardly be expected. Nevertheless, in the Symptoms scale of the KCCQ, assessing the frequency and bothersomeness of edema, fatigue, and dyspnea as well as having to sleep in a sitting position or to use a supporting pillow to ameliorate shortness of breath, the summary score improved by 10 ± 17 points (mean ± standard deviation) in the WS 1442 group compared to 5 ± 14 points in the control group. Moreover, each of the symptoms assessed showed a more favorable outcome in patients with co-administered WS 1442 (Fig. [7](#Fig7){ref-type="fig"}). The validity of the QoL results is limited by potential bias attributable to the open-label design of the study and may deserve confirmation in an adequately powered, double-blind, placebo-controlled trial. The incidence rate of AEs in patients receiving WS 1442 was lower than in those using exercise training alone (13 vs. 17%).Fig. 7Average change in frequency and intensity of heart failure symptoms assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ) (from \[[@CR45]\], Fig. [4](#Fig4){ref-type="fig"})

Benefit-Risk Assessment and Conclusions {#Sec7}
=======================================

Although congestive heart failure may affect people of all ages, most of the burden is borne by individuals aged ≥ 65 years, who account for more than 80% of the deaths and cases of the disease existing in the USA and Europe \[[@CR65]\]. In this elderly, often multimorbid population, the resulting polypharmacy is associated with an exponential increase of the risk of adverse effects \[[@CR66], [@CR67]\] that may ultimately lead to increased mortality \[[@CR68], [@CR69]\]. The use of drugs that have a favorable safety profile and a low potential for drug interactions is therefore crucial \[[@CR70]\].

There is uniform agreement among researchers that *Crataegus* preparations cause few and mainly transient, non-serious adverse effects (e.g., \[[@CR36], [@CR45], [@CR46], [@CR52]\]). For WS 1442, no serious adverse reactions have been observed at all to date. In clinical trials, including a large-scale, long-term mortality study with patients receiving polydrug treatment for heart failure (e.g., ACE inhibitors, β-receptor blockers, spironolactone, digitalis, and nitrates in patients with LVEF \< 35%), no safety signals and no indications of possible drug interactions were observed \[[@CR40]\], and an interaction with digoxin, which is widely used in HFrEF, has been excluded, thus allowing its safe co-administration \[[@CR47]\]. It is therefore concluded that *Crataegus* extract WS 1442 has a very favorable safety profile even when administered as a part of a polydrug regimen.

The SPICE study did not demonstrate an additional beneficial effect of co-administered WS 1442 on mortality in addition to an existing anti-heart failure treatment regimen individually prescribed in accordance with applicable guidelines, but there is encouraging evidence that WS 1442 may reduce the risk of cardiac mortality and sudden cardiac death at least in a subgroup of patients (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}) \[[@CR40]\].

Randomized, controlled studies demonstrate that WS 1442 improves cardiac performance and exercise tolerance in patients with mild to moderately severe heart failure. Moreover, the herbal medicinal product has an ameliorating effect on heart failure emergent symptoms such as edema, dyspnea, and fatigue, and thus alleviates the disease burden of the patients and leads to an improvement of health-related QoL. Importantly, unlike for some other drugs which were also shown to improve such outcomes (e.g., \[[@CR71]\]), no signals were observed that may adversely affect survival.

HFrEF is commonly defined as heart failure with LVEF ≤ 40%, and HFpEF implies LVEF ≥ 50%, whereas patients with LVEF between 41 and 49% may be regarded as suffering from borderline HFpEF (e.g., \[[@CR51]\]). It should be noted that patients of both types of heart failure suffer from similar clinical symptoms. Among the studies considered in this review, the patients of the SPICE study \[[@CR40]\], the HERB CHF study \[[@CR43]\], and the study reported by Eichstädt et al. \[[@CR60]\] suffered from HFrEF, whereas those of the study published by Härtel et al. \[[@CR45]\] suffered from HFpEF. The protocols of the remaining trials reviewed for efficacy of WS 1442 did not include eligibility criteria for LVEF, but three trials required heart failure according to NYHA class II \[[@CR55]--[@CR57]\], whereas one required NYHA class III \[[@CR37]\]. Although there is no clear association between the NYHA functional classification and LVEF \[[@CR49]\], patients with class II heart failure have been found to mainly exhibit LVEF \> 40% (e.g., \[[@CR72]\]), and thus the majority of patients in these trials may likely have suffered from HFpEF.

We agree with the authors of the Cochrane review who concluded that "there is a significant benefit in symptom control and physiologic outcomes from hawthorn extract as an adjunctive treatment for chronic heart failure" \[[@CR52]\] (p. 2). In HFrEF, WS 1442 has been shown to improve functional capacity and heart failure-associated symptoms without causing any safety issues despite long-term polypharmacy in a particularly vulnerable patient population. The improvement of functional capacity and symptoms is now recognized as an important objective of heart failure treatment, on one level with the reduction of mortality and hospitalization \[[@CR49]\]. The administration of WS 1442 in addition to a guideline polydrug treatment in HFrEF appears to be justified since the anticipated benefit to the patients clearly outweighs the additional risk. In this context, it should be noted that the mortality studies confirming the efficacy of β-blockers, ACE inhibitors and mineralocorticoid receptor antagonists were all performed in patients with LVEF ≤ 35 or ≤ 40% so that a beneficial effect in patients with LVEF \> 40% is unproven \[[@CR51]\]. Since HFpEF is commonly understood to require LVEF ≥ 50%, WS 1442 may help to close the therapeutic gap between HFrEF and HFpEF, but more studies are needed to corroborate this benefit

A favorable effect on mortality in HFpEF has not been demonstrated for any drug to date. Instead of proposing a gold standard treatment, current guidelines \[[@CR49], [@CR51]\] are therefore limited to recommending treatments targeting symptom amelioration. In this context, it is important to note that established standard drugs in heart failure treatment, including digitalis, angiotensin II receptor blockers (including irbesartan and candesartan) \[[@CR73]\], angiotensin-converting enzyme inhibitors \[[@CR74]\], ivabradine \[[@CR75]\], ranolazine \[[@CR76]\], and spironolactone, failed to improve the clinical outcome or had only moderate beneficial effects in HFpEF \[[@CR77]--[@CR80]\]. WS 1442, on the other hand, has been demonstrated to improve functional capacity, disabling symptoms, and health-related QoL and has a positive inotropic effect without causing specific adverse effects. In the absence of a gold standard therapy in HFpEF, WS 1442 may therefore be an important therapeutic option in addition to the current clinical standards.

We consider it a strength of our review that it provides a comprehensive overview of the available pre-clinical and clinical data for WS 1442 and thus enables a well-founded assessment of its benefits and risks in the treatment of heart failure. A limitation is that some of the evidence presented in our review originated from older, comparatively small, and partly uncontrolled research, so confirmation by controlled trials meeting current rigorous scientific standards would be highly welcome.

In conclusion, according to scientific evidence from randomized, controlled clinical trials and post-marketing surveillance data, *Crataegus* extract WS 1442 is a safe herbal medicinal product with proven, patient-relevant benefits regarding functional capacity, symptom control and health-related QoL in HFrEF and HFpEF. The observed clinical effects of the product can be explained by pre-clinical findings regarding its mode of action. WS 1442 has therefore been shown to have a positive benefit-risk profile for the treatment of both HFrEF and HFpEF as add-on therapy to current clinical practices.

WS^®^ 1442 is the active substance of Crataegutt^®^ (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany).
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